|
Roche Asthma Drug Meets Primary Endpoint In Phase II Study
Fox Business VX) Thursday said that a phase II study of its investigational asthma treatment lebrikizumab met its primary endpoint in a mid-stage trial. –Lebrikizumab isa humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine. … IL-13 Blocker Helps Asthma Control Experimental Drug Promising Against Tough-to-Treat Asthma Roche asthma drug shows promise in mid-stage trial |
View full post on asthma – Google News